Phase 1, Dose Escalation and Dose-Expansion Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This study is a first-in-human, Phase 1, open-label study that will evaluate safety and
anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma
(R/R MM).